b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="eid" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2681116/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries </title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681116/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Emerging Infectious Diseases" /><meta name="citation_title" content="Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries " /><meta name="citation_authors" content="David S. Fedson" /><meta name="citation_date" content="March 2009" /><meta name="citation_issue" content="3" /><meta name="citation_volume" content="15" /><meta name="citation_firstpage" content="365" /><meta name="citation_doi" content="10.3201/eid1503.080857" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2681116/?report=abstract" /><meta name="citation_pmid" content="19239746" /><meta name="DC.Title" content="Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries " /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Centers for Disease Control and Prevention" /><meta name="DC.Contributor" content="David S. Fedson" /><meta name="DC.Date" content="2009 Mar" /><meta name="DC.Identifier" content="10.3201/eid1503.080857" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries " /><meta property="og:type" content="article" /><meta property="og:description" content="Developing countries face unique difficulties preparing for an influenza pandemic. Our current top-down approach will not provide these countries with adequate supplies of vaccines and antiviral agents. Consequently, they will have to use a bottom-up ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681116/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-eid.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2681116/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2681116/pdf/08-0857_finalP.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1B6702E99C89F10000000000F600F6.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/782/">Emerg Infect Dis</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/177893/">v.15(3); 2009 Mar</a></li><li class="accid">PMC2681116</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-eid.gif" alt="Logo of eid" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,500,75" alt="Emerging Infectious Diseases" title="Emerging Infectious Diseases" href="http://wwwnc.cdc.gov/eid/" ref="reftype=publisher&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Emerg Infect Dis</span>. 2009 Mar; 15(3): 365\xe2\x80\x93371. </span></div><div>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.3201%2Feid1503.080857" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.3201/eid1503.080857</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2681116</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/19239746">19239746</a></div></div></div></div><h1 class="content-title">Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries </h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Fedson%20DS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=19239746">David S. Fedson</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup></div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140222344164800_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140222344164800_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140222344164800_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1">University of Virginia, Charlottesville, Virginia, USA (retired)</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="cor1">Address for correspondence: David S. Fedson, 57 Chemin du Lavoir, 01630 Sergy Haut, France; email: <a href="mailto:dev@null" data-email="rf.oodanaw@nosdefd" class="oemail">rf.oodanaw@nosdefd</a></div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140222344164800_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2681116/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm140222338057312" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140222338057312title">Abstract</h2><!--article-meta--><div><p id="__p2" class="p p-first-last">Developing countries face unique difficulties preparing for an influenza pandemic. Our current top-down approach will not provide these countries with adequate supplies of vaccines and antiviral agents. Consequently, they will have to use a bottom-up approach based on inexpensive generic agents that either modify the host response to influenza virus or act as antiviral agents. Several of these agents have shown promise, and many are currently produced in developing countries. Investigators must primarily identify agents for managing infection in populations and not simply seek explanations for how they work. They must determine in which countries these agents are produced and define patterns of distribution and costs. Because prepandemic research cannot establish whether these agents will be effective in a pandemic, randomized controlled trials must begin immediately after a new pandemic virus has emerged. Without this research, industrialized and developing countries could face an unprecedented health crisis.</p></div><div class="sec"><strong class="kwd-title">Keywords:  </strong><span class="kwd-text">Pandemic, influenza, developing countries, H5N1, generic agents, statins, PPAR agonists, World Health Organization, perspective</span></div></div><div id="idm140222347982080" class="tsec sec headless whole_rhythm"><p id="__p3" class="p p-first">More than a decade ago, the first human cases of disease caused by avian influenza virus A (H5N1) appeared in Hong Kong Special Administrative Region, People&#x02019;s Republic of China. Five years ago, influenza virus A (H5N1) reemerged to cause highly lethal human disease in Southeast Asia. Health officials are concerned that these cases could be the harbinger of the next influenza pandemic. As a result, virtually all industrialized countries and many developing countries have mounted extensive pandemic preparedness efforts. However, as pointed out recently by Oshitani et al., industrialized countries face &#x0201c;unique and difficult issues, which make preparing for a pandemic more challenging&#x0201d; (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862715"><em>1</em></a>).</p></div><div id="__sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec1title">Why a Top-Down Approach to Confronting the Next Pandemic Will Not Work</h2><p id="__p4" class="p p-first">If a pandemic form of influenza virus A (H5N1) emerges within the next few years, all countries will have to depend almost entirely on egg-derived inactivated adjuvanted influenza vaccines. For developing countries, this approach will not succeed. Estimates show that within the first 6&#x02013;9 months of a pandemic outbreak, vaccine companies will be only able to produce enough doses to vaccinate &#x02248;700 million persons (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862731"><em>2</em></a>). This number is less than the combined populations of the 9 countries that produce almost all of the world&#x02019;s seasonal influenza vaccines. These countries will first use their vaccines to ensure that their own populations are protected. Non&#x02013;vaccine-producing countries, both industrialized and developing, will have to wait.</p><p id="__p5">In 2005, a representative of the World Health Organization (WHO) Global Programme on Influenza concluded that &#x0201c;most developing countries will have no access to a vaccine during the first wave of a pandemic and perhaps throughout its duration&#x0201d; (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862720"><em>2</em></a>). Since then, WHO has worked to build a stockpile of &#x02248;1500 million doses of vaccine against influenza virus A (H5N1) for developing countries (<a href="#R3" rid="R3" class=" bibr popnode"><em>3</em></a>), and 2 companies have pledged to provide WHO with 110 million doses. In 2007, a WHO scientific consultation on how to use this stockpile concluded, &#x0201c;If there is sufficient early warning that an outbreak of influenza (H5N1) is due to a virus that is capable of sustained human-to-human transmission, then theoretically there may be a relatively limited &#x02018;window of opportunity&#x02019; to stop the spread of the virus before it spreads nationally or internationally. &#x02026; However, a containment effort would be feasible only in settings where the number of localized cases are [sic] still limited, where adequate logistical support is available, and where the national government is supported by international assistance&#x0201d; (<a href="#R3" rid="R3" class=" bibr popnode"><em>3</em></a>). The vaccine stockpile on which these efforts would depend does not yet exist.</p><p id="__p6">Several industrialized countries are stockpiling vaccines against influenza virus A (H5N1) that might be used for prepandemic vaccination, but Oshitani et al. note that &#x0201c;both pandemic and prepandemic vaccines would not be available in developing countries unless an international mechanism exists to share such vaccine with them at low cost&#x0201d; (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862718"><em>1</em></a>). Even if limited supplies of vaccines could be produced for developing countries, no international mechanism is in place to pay for and distribute the vaccines, and WHO has yet to announce plans to set one up. Thus, when the next pandemic virus emerges, almost no vaccines will be available in developing countries to slow its spread (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862721"><em>1</em></a><em>,</em><a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862753"><em>2</em></a>).</p><p id="__p7">Because global supplies of vaccines against pandemic viruses will be limited, government officials in a few industrialized countries have placed their hopes on stockpiles of antiviral agents, primarily oseltamivir, an expensive neuraminidase inhibitor. In 2005, WHO established its Southeast Asian Influenza Clinical Research Network to study neuraminidase inhibitor treatment of patients infected with viruses that possess pandemic potential (<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862706"><em>4</em></a>). However, influenza virus A (H1N1) has developed resistance to oseltamivir, and similar antiviral resistance could develop in a future pandemic virus. Five million treatment courses (10 doses per patient) of oseltamivir have been donated to a WHO stockpile, but WHO has no plans to dramatically increase the size of this stockpile. On their own, the governments of a few countries that do not produce influenza vaccines or antiviral agents have purchased supplies of oseltamivir, but their stockpiles are sufficient to treat only 1% of their combined populations (D.S. Fedson, unpub. data). Not surprisingly, developing countries themselves &#x0201c;will not allocate scarce resources to stockpile significant quantities of oseltamivir for an unpredictable influenza pandemic&#x0201d; (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862719"><em>1</em></a>). Clearly, the limited supplies of antiviral agents available to developing countries where these infections now occur will scarcely have any effect on a pandemic after it starts to spread.</p><p id="__p8">Influenza virologists report that recent isolates of highly pathogenic influenza viruses (H5N1 and H7N1) have acquired molecular characteristics suggesting they might become more easily transmissible among humans (<a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862743"><em>5</em></a><em>,</em><a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862714"><em>6</em></a>). In Indonesia, physicians have reported that everyone infected with the clade 2 influenza virus A (H5N1) who did not receive antiviral treatment has died (<a href="/pmc/articles/PMC2681116/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>) (<a href="#R7" rid="R7" class=" bibr popnode"><em>7</em></a>). Given extremely limited global supplies of antiviral agents, this is a terrifying observation. If a pandemic virus were to emerge with a level of virulence approaching that of influenza virus A (H5N1) in Indonesia, it could lead to a global population collapse. Many influenza virologists doubt this will ever happen and believe instead that influenza virus (H7N7) or reemergent influenza virus (H2N2) could also cause the next pandemic. Chances are they might be right. Moreover, health officials in national governments and international agencies estimate that expected pandemic deaths will be no more than what can be extrapolated from the 1918&#x02013;1920 pandemic (<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862750"><em>8</em></a>). These officials seldom, if ever, use the phrases &#x0201c;population collapse&#x0201d; or &#x0201c;population die off,&#x0201d; and their estimates may also be right. Nonetheless, in a seminal experiment reported in 1974, Webster and Campbell showed that genetic reassortment, the process that gave rise to pandemic viruses in 1957 and 1968, could give rise to a readily transmissible virus of extraordinary virulence (<a href="/pmc/articles/PMC2681116/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure</span></a>) (<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862751">9</a>). This experiment and human experience with influenza virus A (H5N1) in Indonesia suggest it would be prudent for all countries to plan for something much worse than what occurred in 1918&#x02013;1920.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Relationship between time of onset of antiviral treatment and case-fatality rate in persons with avian influenza A (H5N1) disease in Indonesia, 2003&#x02013;2007*</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140222324352160" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Interval between onset of illness and treatment</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">No. cases</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">No. deaths</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Case-fatality rate, %</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><span class="underline">&#x0003c;</span>24 h</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">0&#x02013;4 d</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">45</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">0&#x02013;6 d</td><td valign="top" align="center" rowspan="1" colspan="1">37</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">65</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x0003e;6 d<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">49<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">40<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">82<hr /></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any treatment</td><td valign="top" align="center" rowspan="1" colspan="1">86</td><td valign="top" align="center" rowspan="1" colspan="1">64</td><td valign="top" align="center" rowspan="1" colspan="1">74</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No treatment<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">33<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">33<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">100<hr /></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">All cases</td><td valign="top" align="center" rowspan="1" colspan="1">119</td><td valign="top" align="center" rowspan="1" colspan="1">97</td><td valign="top" align="center" rowspan="1" colspan="1">82</td></tr></tbody></table></div><div id="largeobj_idm140222324352160" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2681116/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p9">*Adapted from (<a href="#R7" rid="R7" class=" bibr popnode"><em>7</em></a>).</p></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC2681116/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140222376930096" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 08-0857-F.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 08-0857-F.jpg" src="/pmc/articles/PMC2681116/bin/08-0857-F.jpg" /></div><div id="largeobj_idm140222376930096" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2681116/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC2681116/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure</a></div><!--caption a7--><div class="caption"><p id="__p10">Genetic reassortment and genesis of a new pandemic influenza virus. This study was designed to determine whether the selection and transmission of a new reassortant influenza A virus could occur under experimental conditions in vivo that mimic what might occur in nature. Reassortment between 2 antigenically distinct influenza A viruses was studied in turkeys that had been previously immunized to induce low levels of antibodies to the hemagglutinin (H) of a nonlethal turkey influenza virus (Turkey), and to the neuraminidase (N) of a fowl plague virus (FPV), an avian virus that is highly pathogenic for chickens. Twenty-eight days after immunization, the immunized turkeys were sequentially infected, first with the Turkey virus and 4 h later with FPV. During the first few days, both parent viruses were isolated from the infected turkeys, but by day 4 a reassortant virus containing the FPV hemagglutinin and the Turkey neuraminidase (FPV<sub>(H)</sub>&#x02013;Turkey<sub>(N)</sub>) was also isolated; within 2 days it became the dominant virus. All infected turkeys died, and only the FPV<sub>(H)</sub>&#x02013;Turkey<sub>(N)</sub> reassortant virus could be recovered. In a separate experiment, similarly immunized turkeys were again sequentially infected, but on day 5 a group of nonimmunized or selectively immunized turkeys (Turkey<sub>(H)</sub> FPV<sub>(N)</sub>) were placed in the same room. All contact birds soon died of fulminant infection caused by the FPV<sub>(H)</sub>&#x02013;Turkey<sub>(N)</sub> reassortant virus. These experiments demonstrated that under conditions of selective primary immunity, a new virus could be generated through genetic reassortment in vivo and that this reassortant virus could be readily transmitted to contacts. The reassortant virus caused uniformly fatal disease in primary infected and contact birds. Thus, under the conditions of these experiments, genetic reassortment gave rise to a new influenza virus that led to a total population collapse. Adapted from Webster and Campbell (<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862745"><em>9</em></a>).</p></div></div></div><p id="__p11">The current approach to pandemic planning for all countries involves small groups of health officials, influenza scientists, and company executives, most of whom come from industrialized countries. For the foreseeable future, this top-down approach will be incapable of providing developing countries with timely supplies of affordable vaccines and antiviral agents. (Most industrialized countries that do not produce influenza vaccines will have similar difficulties, at least for the first pandemic wave.) The Indonesian Health Minister, for one, understands this. With little prospect that people in her country will be able to obtain vaccines against pandemic viruses, she precipitated a standoff with WHO by announcing in February 2007 that unless Indonesia is able to gain access to supplies of vaccines against pandemic viruses, her country will no longer share its influenza viruses A (H5N1) with WHO&#x02019;s laboratory-based surveillance system (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862716"><em>2</em></a>). Despite unorthodox arguments (<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862728"><em>10</em></a>), her position has garnered wide support from the health ministers of many developing countries (<a href="#R11" rid="R11" class=" bibr popnode"><em>11</em></a>). Recently, Indonesia agreed to share influenza virus A (H5N1) sequences (not the viruses themselves) with the Global Initiative on Sharing Avian Influenza Data, but the country no longer promptly reports deaths from influenza virus A (H5N1), in defiance of new International Health Regulations. WHO has been unable to come up with a solution to this impasse.</p><p id="__p12" class="p p-last">In identifying the major issues and challenges of a pandemic threat facing developing countries, Oshitani et al. have called for better preparedness planning, improved systems for medical care and public health, expanded use of nonpharmaceutical interventions, and strengthened core capacities for seasonal influenza surveillance and vaccination (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862732"><em>1</em></a>). They recognize that this is a challenge few developing countries will be able to meet, but go on to say, &#x0201c;Preparing for a pandemic by simply strengthening preparedness within a single country is not possible. A pandemic is a global issue, and pandemic preparedness should be considered from a global perspective&#x0201d; (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862744"><em>1</em></a>). In practical terms, what exactly does this mean? The record thus far indicates that truly international efforts to prepare for pandemic vaccination and antiviral use have been meager. In almost all instances, these efforts have been vastly outweighed by efforts that reflect national concerns and interests.</p></div><div id="__sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec2title">A Bottom-Up Approach that Developing Countries Can Use to Confront the Next Pandemic</h2><p id="__p13" class="p p-first">A top-down approach will not ensure that adequate and affordable supplies of vaccines against pandemic viruses and antiviral agents can be produced and distributed in time to protect populations in developing countries. Transferring technology for vaccine and antiviral agent production to a small number of developing countries will proceed slowly and will inevitably fail to meet the needs of neighboring countries not favored by these programs (<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862742"><em>12</em></a>). Consequently, developing countries must consider an alternative bottom-up approach to pandemic control, an approach based on existing healthcare workers and institutions and that uses inexpensive and widely available generic agents that have intrinsic antiviral activities or that modify the host response (<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847064009"><em>13</em></a><em>,</em><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015395"><em>14</em></a>).</p><p id="__p14">Many influenza scientists doubt this approach will work (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015393"><em>14</em></a><em>&#x02013;</em><a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862749"><em>16</em></a>). Nonetheless, as reviewed elsewhere (<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847064011"><em>13</em></a><em>,</em><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015397"><em>14</em></a>), several retrospective studies suggest that outpatient statins (drugs taken to lower cholesterol levels and prevent cardiovascular diseases) reduce 30-day pneumonia mortality rates by &#x02248;50% (<a href="/pmc/articles/PMC2681116/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>) (<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862711"><em>17</em></a><em>&#x02013;</em><a href="#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862703"><em>22</em></a>). Most investigators agree that these observational studies must be interpreted with caution and that promising results should be followed by prospective clinical trials. One such trial is already under way, and a preliminary report has shown that in 67 pneumonia patients in intensive care units, treatment with statins reduced the hospital mortality rate by 51% (p = 0.026) (<a href="#R23" rid="R23" class=" bibr popnode"><em>23</em></a>). Pulmonary investigators also believe that peroxisome proliferator&#x02013;activated receptor (PPAR) &#x003b1; and PPAR&#x003b3; agonists (fibrates and glitazones, respectively) could be used to treat acute lung injury (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015394"><em>14</em></a>). An important experimental study has shown that the fibrate gemfibrozil, a PPAR&#x003b1; agonist used to prevent heart disease, reduced mortality rates in mice infected with influenza virus (H2N2) by 54% (<a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862754"><em>24</em></a>). Statins and PPAR agonists have antiinflammatory and immunomodulatory activities, and there is considerable molecular cross-talk between these agents (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015398"><em>14</em></a>). Moreover, combination treatment is safe, and in patients with cardiovascular diseases, clinical benefits are additive. Used either alone or together, this treatment might similarly benefit patients during an influenza pandemic.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Recent studies of patients with pneumonia treated with statins*</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140222347043168" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Investigator (reference)</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Study design and population</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Principal outcome</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Adjusted odds ratio (95% CI) or % reduction (p value)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">van der Garde et al. (<a href="#R17" rid="R17" class=" bibr popnode"><em>17</em></a>)<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">Case&#x02013;control diabetes patients, 4,719/15,322<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">Pneumonia hospitalization<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">0.50 (0.28-0.89)<hr /></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Schlienger et al. (<a href="#R18" rid="R18" class=" bibr popnode"><em>18</em></a>)</td><td valign="top" align="center" rowspan="1" colspan="1">Case&#x02013;control, 1,227/4,734</td><td valign="top" align="center" rowspan="1" colspan="1">Pneumonia hospitalization</td><td valign="top" align="center" rowspan="1" colspan="1">0.63 (0.46&#x02013;0.88)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr /></td><td valign="top" align="left" rowspan="1" colspan="1"><hr /></td><td valign="top" align="center" rowspan="1" colspan="1">30-day pneumonia mortality rate<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">0.47 (0.25&#x02013;0.88)<hr /></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mortensen et al. (<a href="#R19" rid="R19" class=" bibr popnode"><em>19</em></a>)<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">Retrospective cohort, 1,566/7,086<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">30-day pneumonia mortality rate<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">0.54 (0.42&#x02013;0.70)<hr /></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chalmers et al. (<a href="#R20" rid="R20" class=" bibr popnode"><em>20</em></a>)<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">Prospective cohort, 257/750<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">30-day pneumonia mortality rate<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">0.46 (0.25&#x02013; 0.85)<hr /></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Thomsen et al. (21)<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">Retrospective cohort, 1,372/28,528<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">30-day pneumonia mortality rate<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">0.69 (0.58&#x02013;0.82)<hr /></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Majumdar et al. (<a href="#R22" rid="R22" class=" bibr popnode"><em>22</em></a>)</td><td valign="top" align="center" rowspan="1" colspan="1">Prospective cohort, 325/3,090</td><td valign="top" align="center" rowspan="1" colspan="1">Hospital mortality rate and ICU admission (adjusted for administrative data)</td><td valign="top" align="center" rowspan="1" colspan="1">0.88 (0.63&#x02013;1.22)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><hr /></td><td valign="top" align="left" rowspan="1" colspan="1"><hr /></td><td valign="top" align="center" rowspan="1" colspan="1">Hospital mortality rate and ICU admission (adjusted for age, propensity score, clinical data, and functional status)<hr /></td><td valign="top" align="center" rowspan="1" colspan="1">1.10 (0.76&#x02013;1.60)<hr /></td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Choi et al. (<a href="#R23" rid="R23" class=" bibr popnode"><em>23</em></a>)</td><td rowspan="2" valign="top" align="center" colspan="1">Randomized controlled trial, ICU treatment; 33 with atorvastatin and 34 controls</td><td valign="top" align="center" rowspan="1" colspan="1">ICU mortality rate</td><td valign="top" align="center" rowspan="1" colspan="1">45.4 (0.08)</td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">Hospital mortality rate</td><td valign="top" align="center" rowspan="1" colspan="1">51.2 (0.026)</td></tr></tbody></table></div><div id="largeobj_idm140222347043168" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2681116/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p15">*Except for the inpatient randomized controlled trial of Choi et al (<a href="#R23" rid="R23" class=" bibr popnode"><em>23</em></a>), recent treatment in the observational studies was defined as a statin prescription within a period of 30 days (<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862723"><em>18</em></a>) to 90 days before hospitalization for pneumonia. CI, confidence interval; ICU, intensive care unit.</p></div></div><p id="__p16">Other generic agents, some with direct activity against influenza virus, should also be considered (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015396"><em>14</em></a>). Chloroquine, long used as an antimalarial drug, increases endosomal pH and acts as an antiviral agent by impairing virus release into the cytosol. Resveratrol, a polyphenol found in red wine, reduces influenza mortality rates in experimentally infected mice (<a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862705"><em>25</em></a>). Catechins (found in green tea) (<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862717"><em>26</em></a>) and curcumin (turmeric; found in curry powder) (<a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862734"><em>27</em></a>) have numerous cell-signaling effects, suggesting that they too might be beneficial. A combination of agents that act on both the host response and the virus might be required.</p><p id="__p17">It is becoming increasingly difficult for investigators to ignore arguments for treating the host response to influenza. Recently, investigators showed that giving a neuraminidase inhibitor to mice infected with influenza virus A (H5N1) was not nearly as effective as treating the mice with an antiviral agent and 2 immunomodulatory agents, mesalazine, a PPAR&#x003b3; agonist, and celecoxib, a cyclooxygenase (COX)&#x02013;2 inhibitor (<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862702"><em>28</em></a><em>,</em><a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862725"><em>29</em></a>). In this model, targeting the host response to infection was essential for improving survival rates and times. More important, 2 studies in mice showed that intratracheal administration of either a fragment of the PB1-F2 protein of the 1918 influenza virus (<a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862712"><em>30</em></a>) or an inactivated influenza virus A (H5N1) (<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847064012"><em>31</em></a>) caused severe acute lung injury similar to that seen in fatal human cases of influenza (either from the 1918&#x02013;1920 pandemic or from the current H5N1 subtype). In these experimental models, there was no virus replication. Thus, antiviral agents would have had no effect. Although we still lack direct evidence that one or more antiinflammatory and immunomodulatory agents alone would effectively treat human influenza virus A (H5N1) infections, these results and those from the study of influenza virus (H2N2)&#x02013;infected mice treated with gemfibrozil (<a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862726"><em>24</em></a>) suggest these agents might be effective.</p><p id="__p18" class="p p-last">What makes these agents so important is that many of them are currently being produced as generic drugs in developing countries (<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847064010"><em>13</em></a><em>,</em><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015400"><em>14</em></a>). These drugs are inexpensive, could be produced in abundance, and could even be stockpiled and made available for use on the first day of a pandemic. No matter what is accomplished in the years ahead, adequate supplies of vaccines and specific antiviral agents will never be available to persons in developing countries on the first pandemic day.</p></div><div id="__sec3" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec3title">A Research Agenda to Establish a Generic Approach to Pandemic Treatment and Prophylaxis</h2><p id="__p19" class="p p-first">What types of research on generic agents do we need before the pandemic virus appears? First, experimental studies of several candidate treatment regimens must be undertaken in mice infected with influenza virus A (H5N1) or 1918-like viruses (<a href="/pmc/articles/PMC2681116/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). The agents used in these studies might have antiinflammatory and immunomodulatory or antiviral properties (some might have both), but all must be generic agents that are currently produced in developing countries. Admittedly, these experimental studies in mice will have limitations (<a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862740"><em>32</em></a>), but they should identify avenues for further research. Once a few treatment regimens have been shown to be effective in mice, they should be tested in ferrets. Later, 2 or 3 of the most promising regimens should be tested in nonhuman primates.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Research agenda to establish whether generic agents could be used for treatment and prophylaxis of a pandemic caused by a subtype H5N1-like influenza</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140222339845920" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">1. \tTest candidate treatment regimens in mice, ferrets, and nonhuman primates to identify specific generic agents that might be effective in managing a pandemic</th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">2. \tStudy promising generic treatments in cell culture and animals to define the molecular mechanisms that explain their beneficial effects against influenza virus A (H5N1) and 1918-like influenza viruses</th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">3. \tConduct a global analysis to identify developing countries where these generic agents are produced and determine quantities produced, surge capacities, patterns of distribution, and costs to public programs</th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">4. \tEstablish an international process to coordinate or manage the stockpiling of generic agents and/or their distribution once a pandemic virus has emerged</th></tr><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">5. \tPlan to conduct randomized controlled trials of promising generic treatments immediately after the emergence of a new pandemic virus</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"></td></tr></tbody></table></div><div id="largeobj_idm140222339845920" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2681116/table/T3/?report=objectonly">Open in a separate window</a></div></div><p id="__p20">After demonstrating the effectiveness of 1 or more treatment regimens in animals, influenza virologists should then use in vitro systems to define the molecular mechanisms responsible for their protective activity. However, some of these agents will have broader effects on the host response. For example, although administering a COX-2 inhibitor along with a PPAR&#x003b3; agonist improved survival rates and times in mice infected with influenza virus A (H5N1) (<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862708"><em>21</em></a>), another study showed that selective COX-2 inhibition was detrimental to the resolution of acute lung injury (<a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862707"><em>33</em></a>). Most influenza scientists focus their research on the virus or on cell-signaling events associated with viral pathogenesis (<a href="#R34" rid="R34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862729"><em>34</em></a>). Yet the pathophysiologic effects of severe infections involve the entire host, something well known to researchers who study sepsis (<a href="#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862738"><em>35</em></a><em>&#x02013;</em><a href="#R37" rid="R37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862724"><em>37</em></a>). Their studies have shown that statins and PPAR agonists stabilize myocardial and microvascular function, preserve integrity of pulmonary endothelial cell tight junctions and prevent pulmonary edema, and promote resolution of acute inflammation (<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847064008"><em>13</em></a><em>,</em><a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_850015399"><em>14</em></a>). Thus, other investigators with laboratory and clinical expertise in critical care, cardiopulmonary diseases, and endocrinology and metabolism must be recruited to explore in animals the molecular mechanisms underlying these broad treatment effects on the host. However, in undertaking this research, investigators must not forget that their primary goal is to find effective ways to manage a pandemic in populations and not simply to explain in more precise terms the harmful effects of pandemic virus infection in individuals.</p><p id="__p21">While these studies are under way, an analysis should be undertaken for each candidate agent to determine which companies produce them, where each is manufactured, annual levels of production (and surge capacity), patterns of distribution to other developing countries, and costs for public markets (<a href="/pmc/articles/PMC2681116/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Special attention must be given to companies that follow Good Manufacturing Practices to minimize the risk that some of these agents might be counterfeit. When animal studies have defined 1 or more promising regimens, an international process must be set up to develop logistics for financing, producing, and distributing each agent.</p><p id="__p22">Where feasible, clinical trials of promising treatment regimens might be undertaken in patients with severe seasonal influenza. In a few instances, clinicians might choose to treat patients infected with influenza virus A (H5N1) on a compassionate basis (<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862730"><em>12</em></a>). However, none of these limited studies will guarantee that promising treatments in the prepandemic period will be effective against a true pandemic virus. Thus, careful plans must be made during the prepandemic period that will enable investigators to conduct randomized controlled trials of promising generic regimens during the early weeks of a new pandemic. If the case-fatality rate is similar to that of influenza virus A (H5N1) (&#x02248;60%), trials will not need to be large (<a href="/pmc/articles/PMC2681116/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a>). Within a few days, investigators should be able to recruit sufficient numbers of patients to satisfy statistical requirements.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T4"><h3>Table 4</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Sample size requirements for a randomized controlled trial of treatment to reduce deaths in a pandemic caused by a subtype H5N1-like influenza*</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140222345542704" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th valign="bottom" colspan="2" align="center" scope="colgroup" rowspan="1">Case-fatality rate, %<hr /></th><th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Reduction in no. deaths, %</th><th valign="bottom" colspan="3" align="center" scope="colgroup" rowspan="1">Total sample size (power)<hr /></th></tr><tr><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Untreated</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Treated</th><th valign="bottom" colspan="1" align="center" scope="colgroup" rowspan="1">80%</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">90%</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">95%</th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">37.5</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">530</td><td valign="top" align="center" rowspan="1" colspan="1">690</td><td valign="top" align="center" rowspan="1" colspan="1">850</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">140</td><td valign="top" align="center" rowspan="1" colspan="1">170</td><td valign="top" align="center" rowspan="1" colspan="1">210</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">12.5</td><td valign="top" align="center" rowspan="1" colspan="1">75</td><td valign="top" align="center" rowspan="1" colspan="1">60</td><td valign="top" align="center" rowspan="1" colspan="1">80</td><td valign="top" align="center" rowspan="1" colspan="1">90</td></tr></tbody></table></div><div id="largeobj_idm140222345542704" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2681116/table/T4/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p23">*1:1 randomization of persons to the 2 treatment groups, &#x003b1;&#x000a0;=&#x000a0;0.05 (2-sided), &#x003c7;<sup>2</sup> test (continuity corrected). The example shown assumes a case-fatality rate of 50%, which is similar to what has been seen for patients infected with influenza virus A (H5N1). If a new pandemic virus is associated with a lower case-fatality rate, sample sizes required to show similar reductions in case-fatality rates would have to be larger.</p></div></div><p id="__p24">Planning for clinical trials during the prepandemic period must start with identifying clinical investigators who will conduct these trials and institutions that will sponsor their work. Supplies of the agents to be tested must be set aside, study protocols written, and ethical approval obtained. A mechanism for rapid regulatory approval must be developed to enable trials to be conducted wherever the pandemic virus first emerges. A financing mechanism must be established that enables immediate access to funds necessary to support the trials. Finally, an internet-based communication strategy must be devised that ensures prompt dissemination of study results to physicians and health officials worldwide.</p><p id="__p25">None of this research on generic agents will be possible without international coordination. Thus far, the top-down approach that has characterized vaccine and antiviral research and development has lacked an international system for coordination and management to ensure rapid progress (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862746"><em>2</em></a>). Likewise, nothing has been done to ensure worldwide production and distribution of the vaccines and antiviral agents being developed. A similar approach must not be allowed to govern the research agenda for generic agents.</p><p id="__p26" class="p p-last">Experience with the severe acute respiratory syndrome (SARS) in 2003 shows us how we could do much better. When SARS first came to international attention, WHO quickly established 3 virtual networks of experienced virologists, clinicians, and epidemiologists (<a href="#R38" rid="R38" class=" bibr popnode"><em>38</em></a>). By sharing experiences and findings on secure websites and in daily teleconferences, investigators soon identified and sequenced the SARS coronavirus, defined the clinical features of the disease, and established practical measures for clinical management and epidemiologic control. Surprisingly, WHO has not set up a similar system to coordinate research and development of vaccines against pandemic viruses and antiviral agents, despite the far greater threat to global health inherent in an influenza (H5N1) pandemic (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862737"><em>2</em></a>). Given escalating pressure from developing countries, WHO can ill afford to adopt the same slow approach to establishing the scientific basis for using inexpensive and widely available generic agents for pandemic control.</p></div><div id="__sec4" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec4title">Conclusions</h2><p id="__p27" class="p p-first">Oshitani et al. correctly emphasize that preparing for the next pandemic requires a global perspective, but this does not necessarily mean that the measures used to confront the pandemic in developing countries must be supplied through an internationally organized top-down process. An international process will surely be required for distributing vaccines and antiviral agents, but experience indicates that the process will be slow and cumbersome and supplies of these agents will remain scarce (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_170862722"><em>2</em></a>). Nonetheless, developing countries will need abundant supplies of effective agents, and abundance will be guaranteed only if these agents are generic, inexpensive, and produced in developing countries themselves.</p><p id="__p28" class="p p-last">It is too soon to know whether generic agents could be used to confront the next influenza pandemic, yet developing countries lack realistic alternatives. For this reason, their leaders must convince scientists and international organizations, including WHO, of the urgent need for research to determine whether these inexpensive agents could mitigate the effects of a pandemic. Otherwise, developing and industrialized countries alike could be faced with an unprecedented global health crisis.</p></div><div id="idm140222345208624" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140222345208624title">Acknowledgments</h2><div class="sec"><p id="__p30">The author thanks Charles Liss for calculating sample sizes (Table 4) and Astutie Michel for preparing the figure.</p></div></div><div id="idm140222345207616" class="tsec sec headless whole_rhythm"><h2 class="head no_bottom_margin" id="idm140222345207616title">Biography</h2><div class="bio"><div class="left">&#x02022;\xc2\xa0</div><p id="__p31" class="p p-first-last">Dr Fedson is a former professor of medicine at the University of Virginia and former Director of Medical Affairs in Europe for Aventis Pasteur MSD (now Sanofi Pasteur MSD). Since retiring in 2002, he has continued to write and lecture about influenza vaccination, pandemic preparedness, and the potential for using generic agents for pandemic treatment and prophylaxis.</p></div> </div><div id="idm140222340584720" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140222340584720title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm140222340584592"><p id="__p29" class="p p-first-last"><em>Suggested citation for this article</em>: Fedson DS. Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis [serial on the Internet]. 2009 Mar [<em>date cited</em>]. Available from <a href="http://www.cdc.gov/EID/content/15/3/365.htm" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.cdc.gov/EID/content/15/3/365.htm</a></p></p></div></div><div id="idm140222326087808" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140222326087808title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1.  <span class="citation">Oshitani H, Kamigaki T, Suzuki A <span class="ref-title">Major issues and challenges of influenza pandemic preparedness in developing countries. </span><span class="ref-journal">Emerg Infect Dis</span> 2008;<span class="ref-vol">14</span>:875&#x02013;80 10.3201/eid1406.070839 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2600290/">PMC free article</a>]</span> [<a href="/pubmed/18507896" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.3201%2Feid1406.070839" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Major+issues+and+challenges+of+influenza+pandemic+preparedness+in+developing+countries.&amp;volume=14&amp;publication_year=2008&amp;pages=875-80&amp;pmid=18507896&amp;doi=10.3201/eid1406.070839&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2.  <span class="citation">Fedson DS, Dunnill P <span class="ref-title">From scarcity to abundance: pandemic vaccines and other agents for &#x0201c;have not&#x0201d; countries. </span><span class="ref-journal">J Public Health Policy</span> 2007;<span class="ref-vol">28</span>:322&#x02013;40 10.1057/palgrave.jphp.3200147 [<a href="/pubmed/17717543" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1057%2Fpalgrave.jphp.3200147" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Public+Health+Policy&amp;title=From+scarcity+to+abundance:+pandemic+vaccines+and+other+agents+for+&#x0201c;have+not&#x0201d;+countries.&amp;volume=28&amp;publication_year=2007&amp;pages=322-40&amp;pmid=17717543&amp;doi=10.1057/palgrave.jphp.3200147&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3.  <span class="citation">World Health Organization Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. WHO scientific consultation. 2007.  Oct 1&#x02013;3; Geneva [cited 2008 Dec 10]. Available from <a href="http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf</a></span></div><div class="ref-cit-blk half_rhythm" id="R4">4.  <span class="citation">Higgs ES, Hayden FG, Chotpitayasunondh T, Whitworth J, Farrar J <span class="ref-title">The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. </span><span class="ref-journal">Antiviral Res</span> 2008;<span class="ref-vol">78</span>:64&#x02013;8 10.1016/j.antiviral.2007.10.008 [<a href="/pubmed/18295355" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.antiviral.2007.10.008" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antiviral+Res&amp;title=The+Southeast+Asian+Influenza+Clinical+Research+Network:+development+and+challenges+for+a+new+multilateral+research+endeavor.&amp;volume=78&amp;publication_year=2008&amp;pages=64-8&amp;pmid=18295355&amp;doi=10.1016/j.antiviral.2007.10.008&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5.  <span class="citation">Chen LM, David CT, Zhou H, Cox NJ, Donis RO <span class="ref-title">Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. </span><span class="ref-journal">PLoS Pathog</span> 2008;<span class="ref-vol">4</span>:e1000072 10.1371/journal.ppat.1000072 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2374906/">PMC free article</a>]</span> [<a href="/pubmed/18497857" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1371%2Fjournal.ppat.1000072" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Pathog&amp;title=Genetic+compatibility+and+virulence+of+reassortants+derived+from+contemporary+avian+H5N1+and+human+H3N2+influenza+A+viruses.&amp;volume=4&amp;publication_year=2008&amp;pages=e1000072&amp;pmid=18497857&amp;doi=10.1371/journal.ppat.1000072&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6.  <span class="citation">Belser JA, Blixt O, Chen LM, Pappas C, Maines TR, Van Hoeven N, et al. <span class="ref-title">Contemporary North America influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. </span><span class="ref-journal">Proc Natl Acad Sci U S A</span> 2008;<span class="ref-vol">105</span>:7558&#x02013;63 10.1073/pnas.0801259105 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2396559/">PMC free article</a>]</span> [<a href="/pubmed/18508975" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.0801259105" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Contemporary+North+America+influenza+H7+viruses+possess+human+receptor+specificity:+implications+for+virus+transmissibility.&amp;volume=105&amp;publication_year=2008&amp;pages=7558-63&amp;pmid=18508975&amp;doi=10.1073/pnas.0801259105&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7.  <span class="citation">Reports of increased survival in bird flu patients taking Tamiflu. International Symposium on Respiratory Viral Infections; 2008.  Mar 2; Singapore [cited 2008 Dec 10]. Available from <a href="http://www.antara.co.id/en/print/?i=1204536377" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.antara.co.id/en/print/?i=1204536377</a></span></div><div class="ref-cit-blk half_rhythm" id="R8">8.  <span class="citation">Murray CJL, Lopez AD, Chin B, Feehan D, Hill KH <span class="ref-title">Estimation of potential global influenza mortality on the basis of vital registry data from the 1918&#x02013;1920 pandemic: a quantitative analysis. </span><span class="ref-journal">Lancet</span> 2006;<span class="ref-vol">368</span>:2211&#x02013;8 10.1016/S0140-6736(06)69895-4 [<a href="/pubmed/17189032" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0140-6736(06)69895-4" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Estimation+of+potential+global+influenza+mortality+on+the+basis+of+vital+registry+data+from+the+1918&#x02013;1920+pandemic:+a+quantitative+analysis.&amp;volume=368&amp;publication_year=2006&amp;pages=2211-8&amp;pmid=17189032&amp;doi=10.1016/S0140-6736(06)69895-4&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9.  <span class="citation">Webster RG, Campbell CH <span class="ref-title">Studies on the origin of pandemic influenza. IV. Selection and transmission of &#x0201c;new&#x0201d; influenza viruses in vivo. </span><span class="ref-journal">Virology</span> 1974;<span class="ref-vol">62</span>:404&#x02013;13 10.1016/0042-6822(74)90402-4 [<a href="/pubmed/4432372" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2F0042-6822(74)90402-4" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=Studies+on+the+origin+of+pandemic+influenza.+IV.+Selection+and+transmission+of+&#x0201c;new&#x0201d;+influenza+viruses+in+vivo.&amp;volume=62&amp;publication_year=1974&amp;pages=404-13&amp;pmid=4432372&amp;doi=10.1016/0042-6822(74)90402-4&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10.  <span class="citation">Fidler DP <span class="ref-title">Influenza virus samples, international law, and global health diplomacy. </span><span class="ref-journal">Emerg Infect Dis</span> 2008;<span class="ref-vol">14</span>:88&#x02013;94 10.3201/eid1401.070700 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2600156/">PMC free article</a>]</span> [<a href="/pubmed/18258086" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.3201%2Feid1401.070700" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Influenza+virus+samples,+international+law,+and+global+health+diplomacy.&amp;volume=14&amp;publication_year=2008&amp;pages=88-94&amp;pmid=18258086&amp;doi=10.3201/eid1401.070700&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11.  <span class="citation">Schnirring L Indonesia claims wide support for virus-sharing stance. Center for Infectious Disease and Research Policy News. 2008.  May 27 [cited 2008 Dec 12]. Available from <a href="http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/may2708sharing.html" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/may2708sharing.html</a></span></div><div class="ref-cit-blk half_rhythm" id="R12">12.  <span class="citation">Fedson DS <span class="ref-title">New technologies for meeting the global demand for pandemic influenza vaccines. </span><span class="ref-journal">Biologicals</span> 2008;<span class="ref-vol">36</span>:346&#x02013;9 10.1016/j.biologicals.2008.07.001 [<a href="/pubmed/18715803" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.biologicals.2008.07.001" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biologicals&amp;title=New+technologies+for+meeting+the+global+demand+for+pandemic+influenza+vaccines.&amp;volume=36&amp;publication_year=2008&amp;pages=346-9&amp;pmid=18715803&amp;doi=10.1016/j.biologicals.2008.07.001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13.  <span class="citation">Fedson DS <span class="ref-title">Pandemic influenza: a potential role for statins in treatment and prophylaxis. </span><span class="ref-journal">Clin Infect Dis</span> 2006;<span class="ref-vol">43</span>:199&#x02013;205 10.1086/505116 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7107836/">PMC free article</a>]</span> [<a href="/pubmed/16779747" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F505116" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Infect+Dis&amp;title=Pandemic+influenza:+a+potential+role+for+statins+in+treatment+and+prophylaxis.&amp;volume=43&amp;publication_year=2006&amp;pages=199-205&amp;pmid=16779747&amp;doi=10.1086/505116&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14.  <span class="citation">Fedson DS <span class="ref-title">Confronting an influenza pandemic with inexpensive generic agents: can it be done? </span><span class="ref-journal">Lancet Infect Dis</span> 2008;<span class="ref-vol">8</span>:571&#x02013;6 10.1016/S1473-3099(08)70070-7 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7128266/">PMC free article</a>]</span> [<a href="/pubmed/18420459" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1473-3099(08)70070-7" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Infect+Dis&amp;title=Confronting+an+influenza+pandemic+with+inexpensive+generic+agents:+can+it+be+done?&amp;volume=8&amp;publication_year=2008&amp;pages=571-6&amp;pmid=18420459&amp;doi=10.1016/S1473-3099(08)70070-7&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15.  <span class="citation">Butler D <span class="ref-title">Cheaper approaches to flu divide flu researchers. </span><span class="ref-journal">Nature</span> 2007;<span class="ref-vol">448</span>:976&#x02013;7 10.1038/448976b [<a href="/pubmed/17728727" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2F448976b" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Cheaper+approaches+to+flu+divide+flu+researchers.&amp;volume=448&amp;publication_year=2007&amp;pages=976-7&amp;pmid=17728727&amp;doi=10.1038/448976b&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16.  <span class="citation">Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261&#x02013;73. [<a href="/pubmed/18199865" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="R17">17.  <span class="citation">van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG <span class="ref-title">Statin therapy and reduced risk of pneumonia in patients with diabetes. </span><span class="ref-journal">Thorax</span> 2006;<span class="ref-vol">61</span>:957&#x02013;61 10.1136/thx.2006.062885 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2121156/">PMC free article</a>]</span> [<a href="/pubmed/16809409" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1136%2Fthx.2006.062885" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Thorax&amp;title=Statin+therapy+and+reduced+risk+of+pneumonia+in+patients+with+diabetes.&amp;volume=61&amp;publication_year=2006&amp;pages=957-61&amp;pmid=16809409&amp;doi=10.1136/thx.2006.062885&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18.  <span class="citation">Schlienger RG, Fedson DS, Jick S, Jick H, Meier C <span class="ref-title">Statins and the risk of pneumonia: a population-based nested case-control study. </span><span class="ref-journal">Pharmacotherapy</span> 2007;<span class="ref-vol">27</span>:325&#x02013;32 10.1592/phco.27.3.325 [<a href="/pubmed/17316144" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1592%2Fphco.27.3.325" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacotherapy&amp;title=Statins+and+the+risk+of+pneumonia:+a+population-based+nested+case-control+study.&amp;volume=27&amp;publication_year=2007&amp;pages=325-32&amp;pmid=17316144&amp;doi=10.1592/phco.27.3.325&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19.  <span class="citation">Mortensen EM, Pugh MJ, Copeland L, Cornell J, Restrepo MI, Anzueto A, et al. <span class="ref-title">Impact of statins and ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia and influenza. </span><span class="ref-journal">Eur Respir J</span> 2008;<span class="ref-vol">31</span>:611&#x02013;7 10.1183/09031936.00162006 [<a href="/pubmed/17959631" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1183%2F09031936.00162006" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+Respir+J&amp;title=Impact+of+statins+and+ACE+inhibitors+on+mortality+for+patients+hospitalized+with+community-acquired+pneumonia+and+influenza.&amp;volume=31&amp;publication_year=2008&amp;pages=611-7&amp;pmid=17959631&amp;doi=10.1183/09031936.00162006&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20.  <span class="citation">Chalmers JD, Singanayagam A, Murray MP, Hill AT <span class="ref-title">Prior statin use is associated with improved outcomes in community-acquired pneumonia. </span><span class="ref-journal">Am J Med</span> 2008;<span class="ref-vol">121</span>:1002&#x02013;7 10.1016/j.amjmed.2008.06.030 [<a href="/pubmed/18954848" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.amjmed.2008.06.030" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Med&amp;title=Prior+statin+use+is+associated+with+improved+outcomes+in+community-acquired+pneumonia.&amp;volume=121&amp;publication_year=2008&amp;pages=1002-7&amp;pmid=18954848&amp;doi=10.1016/j.amjmed.2008.06.030&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21.  <span class="citation">Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT <span class="ref-title">Preadmission use of statins and outcomes after hospitalization with pneumonia. </span><span class="ref-journal">Arch Intern Med</span> 2008;<span class="ref-vol">168</span>:2081&#x02013;7 10.1001/archinte.168.19.2081 [<a href="/pubmed/18955636" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1001%2Farchinte.168.19.2081" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Intern+Med&amp;title=Preadmission+use+of+statins+and+outcomes+after+hospitalization+with+pneumonia.&amp;volume=168&amp;publication_year=2008&amp;pages=2081-7&amp;pmid=18955636&amp;doi=10.1001/archinte.168.19.2081&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22.  <span class="citation">Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ <span class="ref-title">Statins and outcomes in patients admitted to hospital with community acquired pneumonia: a population based prospective cohort study. </span><span class="ref-journal">BMJ</span> 2006;<span class="ref-vol">333</span>:999&#x02013;1004 10.1136/bmj.38992.565972.7C <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1635620/">PMC free article</a>]</span> [<a href="/pubmed/17060337" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1136%2Fbmj.38992.565972.7C" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Statins+and+outcomes+in+patients+admitted+to+hospital+with+community+acquired+pneumonia:+a+population+based+prospective+cohort+study.&amp;volume=333&amp;publication_year=2006&amp;pages=999-1004&amp;pmid=17060337&amp;doi=10.1136/bmj.38992.565972.7C&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23.  <span class="citation">Choi HS, Park MJ, Kang HM, Lim IH, Choi CW, You JH <span class="ref-title">Statin use and mortality in sepsis due to pneumonia. </span><span class="ref-journal">Crit Care Med</span> 2007;<span class="ref-vol">35</span>(<span class="ref-iss">Suppl</span>):1362 10.1097/01.CCM.0000261888.32654.6D [<a href="//dx.doi.org/10.1097%2F01.CCM.0000261888.32654.6D" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Crit+Care+Med&amp;title=Statin+use+and+mortality+in+sepsis+due+to+pneumonia.&amp;volume=35&amp;issue=Suppl&amp;publication_year=2007&amp;pages=1362&amp;pmid=17414732&amp;doi=10.1097/01.CCM.0000261888.32654.6D&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24.  <span class="citation">Budd A, Alleva L, Alsharifi M, Koskinen A, Smytha V, Mullbacher A, et al. <span class="ref-title">Increased survival after gemfibrozil treatment of severe mouse influenza. </span><span class="ref-journal">Antimicrob Agents Chemother</span> 2007;<span class="ref-vol">51</span>:2965&#x02013;8 10.1128/AAC.00219-07 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1932503/">PMC free article</a>]</span> [<a href="/pubmed/17562808" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FAAC.00219-07" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob+Agents+Chemother&amp;title=Increased+survival+after+gemfibrozil+treatment+of+severe+mouse+influenza.&amp;volume=51&amp;publication_year=2007&amp;pages=2965-8&amp;pmid=17562808&amp;doi=10.1128/AAC.00219-07&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25.  <span class="citation">Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cossolino F, et al. <span class="ref-title">Inhibition of influenza A virus replication by resveratrol. </span><span class="ref-journal">J Infect Dis</span> 2005;<span class="ref-vol">191</span>:1719&#x02013;29 10.1086/429694 [<a href="/pubmed/15838800" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F429694" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Inhibition+of+influenza+A+virus+replication+by+resveratrol.&amp;volume=191&amp;publication_year=2005&amp;pages=1719-29&amp;pmid=15838800&amp;doi=10.1086/429694&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26.  <span class="citation">Song JM, Park KD, Lee KH, Byun YH, Park JH, Kim SH, et al. <span class="ref-title">Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. </span><span class="ref-journal">Antiviral Res</span> 2007;<span class="ref-vol">76</span>:178&#x02013;85 10.1016/j.antiviral.2007.07.001 [<a href="/pubmed/17709148" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.antiviral.2007.07.001" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antiviral+Res&amp;title=Biological+evaluation+of+anti-influenza+viral+activity+of+semi-synthetic+catechin+derivatives.&amp;volume=76&amp;publication_year=2007&amp;pages=178-85&amp;pmid=17709148&amp;doi=10.1016/j.antiviral.2007.07.001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27.  <span class="citation">Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, et al. <span class="ref-title">The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. </span><span class="ref-journal">Crit Care Med</span> 2006;<span class="ref-vol">34</span>:1874&#x02013;82 10.1097/01.CCM.0000221921.71300.BF [<a href="/pubmed/16715036" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F01.CCM.0000221921.71300.BF" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Crit+Care+Med&amp;title=The+anti-inflammatory+effect+of+curcumin+in+an+experimental+model+of+sepsis+is+mediated+by+up-regulation+of+peroxisome+proliferator-activated+receptor-gamma.&amp;volume=34&amp;publication_year=2006&amp;pages=1874-82&amp;pmid=16715036&amp;doi=10.1097/01.CCM.0000221921.71300.BF&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28.  <span class="citation">Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, et al. <span class="ref-title">Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. </span><span class="ref-journal">Proc Natl Acad Sci U S A</span> 2008;<span class="ref-vol">105</span>:8091&#x02013;6 10.1073/pnas.0711942105 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2430364/">PMC free article</a>]</span> [<a href="/pubmed/18523003" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.0711942105" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Delayed+antiviral+plus+immunomodulator+treatment+still+reduces+mortality+in+mice+infected+by+high+inoculum+of+influenza+A/H5N1+virus.&amp;volume=105&amp;publication_year=2008&amp;pages=8091-6&amp;pmid=18523003&amp;doi=10.1073/pnas.0711942105&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29.  <span class="citation">Simmons C, Farrar JT <span class="ref-title">Insights into inflammation. </span><span class="ref-journal">N Engl J Med</span> 2008;<span class="ref-vol">359</span>:1621&#x02013;3 10.1056/NEJMcibr0805865 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2730541/">PMC free article</a>]</span> [<a href="/pubmed/18843127" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMcibr0805865" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Insights+into+inflammation.&amp;volume=359&amp;publication_year=2008&amp;pages=1621-3&amp;pmid=18843127&amp;doi=10.1056/NEJMcibr0805865&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30.  <span class="citation">McAuley JL, Hornung F, Boyd KL, Smith AM, McKeon R, Bennick J, et al. <span class="ref-title">Expression of the 1918 influenza A virus PB1&#x02013;F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. </span><span class="ref-journal">Cell Host Microbe</span> 2007;<span class="ref-vol">2</span>:240&#x02013;9 10.1016/j.chom.2007.09.001 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2083255/">PMC free article</a>]</span> [<a href="/pubmed/18005742" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.chom.2007.09.001" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Host+Microbe&amp;title=Expression+of+the+1918+influenza+A+virus+PB1&#x02013;F2+enhances+the+pathogenesis+of+viral+and+secondary+bacterial+pneumonia.&amp;volume=2&amp;publication_year=2007&amp;pages=240-9&amp;pmid=18005742&amp;doi=10.1016/j.chom.2007.09.001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31.  <span class="citation">Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. <span class="ref-title">Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. </span><span class="ref-journal">Cell</span> 2008;<span class="ref-vol">133</span>:235&#x02013;49 10.1016/j.cell.2008.02.043 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7112336/">PMC free article</a>]</span> [<a href="/pubmed/18423196" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.cell.2008.02.043" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Identification+of+oxidative+stress+and+Toll-like+receptor+4+signaling+as+a+key+pathway+of+acute+lung+injury.&amp;volume=133&amp;publication_year=2008&amp;pages=235-49&amp;pmid=18423196&amp;doi=10.1016/j.cell.2008.02.043&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32.  <span class="citation">Mizgerd JP, Skerrett SJ <span class="ref-title">Animal models of human lung disease. </span><span class="ref-journal">Am J Physiol Lung Cell Mol Physiol</span> 2008;<span class="ref-vol">294</span>:L387&#x02013;98 10.1152/ajplung.00330.2007 [<a href="/pubmed/18162603" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1152%2Fajplung.00330.2007" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Physiol+Lung+Cell+Mol+Physiol&amp;title=Animal+models+of+human+lung+disease.&amp;volume=294&amp;publication_year=2008&amp;pages=L387-98&amp;pmid=18162603&amp;doi=10.1152/ajplung.00330.2007&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33.  <span class="citation">Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD <span class="ref-title">Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. </span><span class="ref-journal">J Immunol</span> 2005;<span class="ref-vol">174</span>:5033&#x02013;9 [<a href="/pubmed/15814734" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Cyclooxygenase+2+plays+a+pivotal+role+in+the+resolution+of+acute+lung+injury.&amp;volume=174&amp;publication_year=2005&amp;pages=5033-9&amp;pmid=15814734&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34.  <span class="citation">Korteweg C, Gu J <span class="ref-title">Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. </span><span class="ref-journal">Am J Pathol</span> 2008;<span class="ref-vol">172</span>:1155&#x02013;70 10.2353/ajpath.2008.070791 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2329826/">PMC free article</a>]</span> [<a href="/pubmed/18403604" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.2353%2Fajpath.2008.070791" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=Pathology,+molecular+biology,+and+pathogenesis+of+avian+influenza+A+(H5N1)+infection+in+humans.&amp;volume=172&amp;publication_year=2008&amp;pages=1155-70&amp;pmid=18403604&amp;doi=10.2353/ajpath.2008.070791&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35.  <span class="citation">van der Poll T, Opal SM <span class="ref-title">Host-pathogen interactions in sepsis. </span><span class="ref-journal">Lancet Infect Dis</span> 2008;<span class="ref-vol">8</span>:32&#x02013;43 10.1016/S1473-3099(07)70265-7 [<a href="/pubmed/18063412" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1473-3099(07)70265-7" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Infect+Dis&amp;title=Host-pathogen+interactions+in+sepsis.&amp;volume=8&amp;publication_year=2008&amp;pages=32-43&amp;pmid=18063412&amp;doi=10.1016/S1473-3099(07)70265-7&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36.  <span class="citation">Rittirsch D, Flierl MA, Ward PA <span class="ref-title">Harmful molecular mechanisms in sepsis. </span><span class="ref-journal">Nat Rev Immunol</span> 2008;<span class="ref-vol">8</span>:776&#x02013;87 10.1038/nri2402 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2786961/">PMC free article</a>]</span> [<a href="/pubmed/18802444" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fnri2402" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&amp;title=Harmful+molecular+mechanisms+in+sepsis.&amp;volume=8&amp;publication_year=2008&amp;pages=776-87&amp;pmid=18802444&amp;doi=10.1038/nri2402&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37.  <span class="citation">Carr&#x000e9; JE, Singer M Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta 2008;1777:763&#x02013;71. [<a href="/pubmed/18482575" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="R38">38.  <span class="citation">World Health Organization WHO global conference on severe acute respiratory syndrome (SARS). Where do we go from here? 2003.  Jun 17&#x02013;18 [cited 2008 Dec 10]. Available from <a href="http://www.who.int/csr/sars/conference/june_2003/materials/report/en/index.html" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2681116&amp;issue-id=177893&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.who.int/csr/sars/conference/june_2003/materials/report/en/index.html</a></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">Emerging Infectious Diseases</span> are provided here courtesy of <strong>Centers for Disease Control and Prevention</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2681116/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2681116/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2681116/pdf/08-0857_finalP.pdf">PDF (196K)</a></li> | <li><a href="#" data-citationid="PMC2681116" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2681116%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2681116%2F&amp;text=Meeting%20the%20Challenge%20of%20Influenza%20Pandemic%20Preparedness%20in%20Developing%20Countries%20"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2681116%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="19239746" data-aiid="2681116" data-aid="2681116" data-iid="177893" data-domainid="782" data-domain="eid" data-accid="PMC2681116" data-md5="aeabc0524a76cba9e282217d3165a6b7"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T11:25:34-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1B6702E99C89F10000000000F600F6&amp;ncbi_session=8A1B6702E99CA6D1_0246SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2681116%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=eid&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2681116/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1B6702E99CA6D1_0246SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'